Date published: 2025-10-12

1-800-457-3801

SCBT Portrait Logo
Seach Input

Marbofloxacin (CAS 115550-35-1)

0.0(0)
Write a reviewAsk a question

Alternate Names:
9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic Acid; Marbocyl; Zeniquin
CAS Number:
115550-35-1
Molecular Weight:
362.36
Molecular Formula:
C17H19FN4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Marbofloxacin, identified with the CAS number 115550-35-1, is a synthetic fluoroquinolone compound extensively utilized in microbiological research to study the dynamics of bacterial DNA replication and cell division processes. The principal mechanism of action of Marbofloxacin involves the inhibition of bacterial DNA gyrase and topoisomerase IV. These critical enzymes are responsible for maintaining the supercoiling state of DNA, which is essential for proper DNA replication and segregation during cell division. By binding to these enzymes, Marbofloxacin introduces breaks in the bacterial DNA, prevents the resealing of these breaks, and thus disrupts the replication process, leading to an inhibition of bacterial growth and multiplication. This specific interaction makes Marbofloxacin a valuable tool in research focused on understanding the intricacies of bacterial DNA manipulation and the effects of enzyme inhibition on bacterial viability. Studies using Marbofloxacin have explored its efficacy against a broad spectrum of bacteria, providing insights into the mechanisms of action of fluoroquinolones and the development of resistance. Furthermore, research involving Marbofloxacin has also helped to explain the role of mutation rates in bacterial populations under antibiotic pressure, contributing significantly to the field of microbial genetics and antibiotic resistance studies.


Marbofloxacin (CAS 115550-35-1) References

  1. Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli.  |  Pellet, T., et al. 2006. Res Vet Sci. 80: 324-35. PMID: 16126240
  2. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.  |  Vouldoukis, I., et al. 2006. Vet Parasitol. 135: 137-46. PMID: 16242844
  3. Inclusion of marbofloxacin in PMMA orthopaedic cement: an in vitro experimental study.  |  Cariou, M., et al. 2006. Vet Comp Orthop Traumatol. 19: 106-9. PMID: 16810353
  4. In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals.  |  Farca, AM., et al. 2007. Schweiz Arch Tierheilkd. 149: 265-71. PMID: 17645036
  5. Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.  |  Andraud, M., et al. 2011. Antimicrob Agents Chemother. 55: 756-61. PMID: 21078933
  6. Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.  |  Farca, AM., et al. 2012. Parasitol Res. 110: 2509-13. PMID: 22218923
  7. Novel in vitro systems for prediction of veterinary drug residues in ovine milk and dairy products.  |  González-Lobato, L., et al. 2014. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 31: 1026-37. PMID: 24679113
  8. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.  |  Sun, J., et al. 2015. BMC Vet Res. 11: 293. PMID: 26626889
  9. In Vitro Killing of Canine Urinary Tract Infection Pathogens by Ampicillin, Cephalexin, Marbofloxacin, Pradofloxacin, and Trimethoprim/Sulfamethoxazole.  |  Blondeau, JM. and Fitch, SD. 2021. Microorganisms. 9: PMID: 34835405

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Marbofloxacin, 1 g

sc-211775
1 g
$204.00